Italia markets close in 3 hours 12 minutes

Vertex Pharmaceuticals Incorporated (0QZU.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
320,48+3,27 (+1,03%)
Al 07:16AM GMT. Mercato aperto.
Schermo intero
Chiusura precedente317,21
Aperto0,00
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno0,00 - 0,00
Intervallo di 52 settimane
Volume6.912
Media VolumeN/D
Capitalizzazione823,624M
Beta (5 anni mensile)0,43
Rapporto PE (ttm)0,34
EPS (ttm)9,48
Prossima data utili24 gen 2023 - 30 gen 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second quarter ended June 30, 2022. “We were very pleased to have completed the sale of our complement portfolio during the second quarter to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (“Vertex”) for $60.0 million in cash with up to $5.0 million of that amount due in May 2023. This transaction was the

  • GlobeNewswire

    Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease

    Verve to Receive $25 Million Upfront Payment and $35 Million Equity Investment, as Well as Potential Milestones and RoyaltiesBOSTON and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Verve Therapeutics, Inc. (Nasdaq: VERV) today announced an exclusive, four-year global research collaboration focused on discovering and developing an in vivo gene editing program for a single undisclosed liver disease. Under the terms of the collaboration,

  • GlobeNewswire

    Catalyst Biosciences Sells Complement Portfolio for $60 Million

    SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash. Management Comments“We have been exploring strategic alternatives to monetize our assets and maximize value f